Can-Fite submits Phase 2 Lowe syndrome trial protocol for Piclidenoson to Italy hospital
CANF•Phase 2 protocol submitted to Rome hospital
Can-Fite submitted a Phase 2 trial protocol for Piclidenoson in Lowe syndrome to Bambino Gesù Children’s Hospital in Rome for review.
The open-label, single-center study targets 5 adults over six months, aiming to support regulatory discussions and a potential registration pathway on positive results.
Related News
Fast Track Group partners with Sony Music Entertainment Malaysia on co-branded artist growth platforms
FTRK•
Acurx says FDA open to single Phase 3 trial to support ibezapolstat CDI NDA filing
ACXP•
